Can we differentiate between finerenone, eplerenone and spironolactone in HFmrEF/HFpEF through a Bayesian lens?
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
This editorial refers to ‘Finerenone, eplerenone, and spironolactone in HFpEF: a Bayesian network meta-analysis of efficacy and safety’, by V. Bagattoli et al., https://doi.org/10.1093/ejhf/xuag083. Mineralocorticoid receptor agonists (MRAs) are recommended in the current guidelines for the treatment of heart failure with reduced ejection fraction (HFrEF) with a class IA recommendation.1,2 Results from pivotal trials in patients with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF) have, however, been more mixed3–5. In TOPCAT, a placebo-controlled trial of the steroidal MRA spironolactone, a frequentist analysis of the primary endpoint failed to reach statistical significance. There was, however, a signal of regional heterogeneity which suggested the treatment may be effective. More recently, the non-steroidal MRA finerenone showed significant evidence of a reduction in the rate of total heart failure events and cardiovascular death in the FINEARTS-HF trial. There have been no large outcome-driven trials of eplerenone, another steroidal MRA, in HFmrEF/HFpEF. Crucially, there is no randomized evidence to directly compare the effectiveness of these individual MRAs. Network meta-analysis (NMA) is a method that can fill an evidence gap when no direct evidence is available by making indirect comparisons with a common comparator.
Fields of Study & Subjects
Heart Failure Treatment and Management
Hormonal Regulation and Hypertension
Cardiovascular Function and Risk Factors
Publication details
- Journal / source
- European Journal of Heart Failure
- Volume
- 28
- Issue
- 3
- Pages
- 484–486
- Publication date
- 1 March 2026
- Language
- EN